News

Shanghai Devoxin Bioengineering Co., Ltd., established in 2010, is an ecology-oriented biotechnology enterprise specializing in bioengineering, providing a full chain of products, strain services and technical support. It is committed to delivering integrated solutions that meet international standards for the bio-industry.

As biomanufacturing embraces Industry 4.0, digital twins and AI control are essential. Advanced algorithms require high-fidelity data and precise execution.If AI is the brain of bioreactors, precision hardware is its nerves and muscles.Devoxin provides robust physical infrastructure to eliminate data distortion and execution errors at the source.

The core of the cell therapy upstream process is fermentation and preparation, whose core equipment directly determines downstream efficiency and product quality.Adopting an upstream‑downstream integrated strategy, Diwoxin has developed a high‑end intelligent platform that connects core fermentation equipment with downstream systems to maximize performance and drive the industrialization and standardization of upstream processes.

This article debunks the "simple scale-up" myth in fermentation, highlighting the core differences between shake flasks and industrial fermenters. It underscores that innovations like miniature bioreactors and AI-driven optimization are bridging lab-to-industry gaps, driving the sector toward precision and intelligence.

This article notes that the bioreaction industry is constrained by a rigid cost structure, with competition shifting to cost optimization. It breaks down key costs including substrates, energy, equipment, compliance and labor, analyzes cost-cutting points, and argues that refined full-link operation and professional solutions are critical. Future competitiveness lies in comprehensive cost control.

Synthetic biology-fermentation integration accelerates, driving biomanufacturing. Divoxin offers a reference; applications expand to mRNA vaccines.Challenges: traditional fermentation lags strains; data underutilized; strain construction ignores growth environments.Bridging gaps, collaboration and big data/AI integration are key for biomanufacturing industrialization.

As the core of biomanufacturing, bioreactors were long foreign-monopolized, with traditional methods hindering strain verification. Shanghai Divoxin, with 16 years of experience, broke through with high-performance bioreactors covering laboratory and industrial scenarios. These domestic breakthroughs end import monopoly, cut costs and lay a foundation for China’s biomanufacturing development.

China's biopharmaceutical industry has entered its "second half," centered on "commercialization efficiency," making downstream purification processes a key competitive factor. Traditional batch processes are inefficient and costly. Under pressure from healthcare cost control and overseas competition, the industry urgently needs to reduce costs and increase efficiency through "continuous biological processing" and "process intensification." To overcome the bottleneck of relying on imported core